Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | HTR2A | P28223 | 2/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30001633 | 1.00 | CYP2D6 (0.74) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL10806395 | 0.99 | CYP2D6 (0.72) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| SCHEMBL8702732 | 0.92 | CYP2D6 (0.64) | CYP2D6HTR2AABCB1 | |
| SCHEMBL8706577 | 0.92 | CYP2D6 (0.64) | CYP2D6HTR2AABCB1 | |
| Hydrochloric Acid SCHEMBL8702986 | 0.91 | CYP2D6 (0.63) | CYP2D6HTR2AABCB1 | |
| SCHEMBL8709242 | 0.91 | CYP2D6 (0.63) | CYP2D6HTR2AABCB1 | |
| Hydrochloric Acid SCHEMBL8703891 | 0.91 | CYP2D6 (0.63) | CYP2D6HTR2AABCB1 | |
| SCHEMBL8708750 | 0.91 | CYP2D6 (0.63) | CYP2D6HTR2AABCB1 | |
| SCHEMBL8708818 | 0.91 | CYP2D6 (0.63) | CYP2D6HTR2AABCB1 | |
| Hydrochloric Acid SCHEMBL8704853 | 0.90 | CYP2D6 (0.61) | CYP2D6HTR2AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3618819-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018204713-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | EXCIVA UG (HAFTUNGSBESCHRÄNKT) (DE) | 2018-11-08 | — | — | WO | disclosed |
| EP-0072942-B1 | PHARMACEUTICALLY ACTIVE (3-AMINOPROPOXY)-BIBENZYL DERIVATIVES | MITSUBISHI KASEI CORPORATION (JP) | 1987-03-04 | — | — | EP | disclosed |
| US-4599419-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES, INC. (JP) | 1986-07-08 | — | — | US | disclosed |
| US-4485258-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1984-11-27 | — | — | US | disclosed |
| EP-0072942-A2 | Pharmaceutically active (3-aminopropoxy)-bibenzyl derivatives | MITSUBISHI KASEI CORPORATION (JP) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | CYP2D6 17/4885HTR2A 2/4885ABCB1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.